This Article Full Text Full Text (PDF) All Versions of this Article: 111/23/3016    most recent CIRCULATIONAHA.105.557652v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grundy, S. M. Search for Related Content PubMed PubMed Citation Articles by Grundy, S. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Statins Related Collections Other arteriosclerosis

(Circulation. 2005;111:3016-3019.)
© 2005 American Heart Association, Inc.

Editorial

The Issue of Statin Safety

Where do We Stand?

From the Center for Human Nutrition and the Departments of Clinical Nutrition and Internal Medicine, University of Texas Southwestern Medical Center at Dallas.

Correspondence to Scott M. Grundy, MD, PhD, Center for Human Nutrition and Departments of Clinical Nutrition and Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Y3.206, Dallas, TX 75390-9052. E-mail scott.grundy@utsouthwestern.edu

Key Words: Editorials • statins • safety • adverse effects

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Statins are first-line therapy for reducing low-density lipoprotein (LDL) levels in patients at high risk for atherosclerotic cardiovascular disease (ASCVD).^1,2 These agents are being used in millions of high-risk people worldwide. Many others receive statins for primary prevention. The total number can only be expected to rise with time. Although favorable results from a large number of controlled clinical trials underpin the benefits of statin therapy,² it is not surprising that the safety of statins has received much attention. Controlled trials and clinical practice have demonstrated that they generally are safe; in fact, the frequency of clinically significant side effects is quite low. In rare patients, nonetheless, side effects can occur and occasionally are serious. Most serious among these is severe myopathy (rhabdomyolysis), which can cause acute renal failure. In a small percentage of patients, statins elevate serum transaminases. There is little or no evidence that statins cause progressive liver disease³; nevertheless, persistent elevations in transaminases can be perplexing. Other less serious side effects may occur. One of these that was demonstrated recently is low-grade proteinuria, likely due to a statin-induced inhibition of proximal tubular reabsorption of protein.⁴ To date, no evidence exists that this is accompanied by pathological tubular injury or progression to chronic renal failure.

See p 3051

Side effects of statins tend to be dose related. Most side effects, including myopathy, disappear on withdrawal of the medication. Even with severe myopathy, most patients survive with supportive measures, although fatalities occasionally occur. For example, Omar and Wilson⁵ . . . [Full Text of this Article]

This article has been cited by other articles:

				M. Rajaram Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin use BMJ Case Reports, February 2, 2009; 2009(jan27_1): bcr0720080412 - bcr0720080412. [Abstract] [Full Text]

				R. H. Samson The Role of Statin Drugs in the Management of the Peripheral Vascular Patient Vascular and Endovascular Surgery, August 1, 2008; 42(4): 352 - 366. [Abstract] [PDF]

				M. Settergren, F. Bohm, L. Ryden, and J. Pernow Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease Eur. Heart J., July 2, 2008; 29(14): 1753 - 1760. [Abstract] [Full Text] [PDF]

				M. Al-Shabrawey, M. Bartoli, A. B. El-Remessy, G. Ma, S. Matragoon, T. Lemtalsi, R. W. Caldwell, and R. B. Caldwell Role of NADPH Oxidase and Stat3 in Statin-Mediated Protection against Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3231 - 3238. [Abstract] [Full Text] [PDF]

				J L Walker, G H Smith, M S Gaston, and C M Robinson Spontaneous compartment syndrome in association with simvastatin-induced myositis Emerg. Med. J., May 1, 2008; 25(5): 305 - 306. [Abstract] [Full Text] [PDF]

				K. Josan MD, S. R. Majumdar MD MPH, and F. A. McAlister MD MSc The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials Can. Med. Assoc. J., February 26, 2008; 178(5): 576 - 584. [Abstract] [Full Text] [PDF]

				J. R. Holman Some Docs in Denial About Statin Side Effects DOC News, December 1, 2007; 4(12): 1 - 12. [Full Text]

				G. A. Schmidt, J. D. Hoehns, J. L. Purcell, R. L. Friedman, and Y. Elhawi Severe Rhabdomyolysis and Acute Renal Failure Secondary to Concomitant Use of Simvastatin, Amiodarone, and Atazanavir J Am Board Fam Med, July 1, 2007; 20(4): 411 - 416. [Abstract] [Full Text] [PDF]

				An Analysis of Rosuvastatin's Safety Record Journal Watch Cardiology, June 10, 2005; 2005(610): 1 - 1. [Full Text]